<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="199" ids="26708">sodium</z:chebi>-<z:chebi fb="105" ids="17234">glucose</z:chebi> co-transporter-2 (SGLT2) is a low-affinity transport system that is specifically expressed in the kidney and plays an important role in renal <z:chebi fb="105" ids="17234">glucose</z:chebi> reabsorption in the proximal tubule </plain></SENT>
<SENT sid="1" pm="."><plain>Competitive inhibition of SGLT2 therefore represents an innovative therapeutic strategy for the treatment of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and/or <z:hpo ids='HP_0001513'>obesity</z:hpo> in patients with type 1 or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by enhancing <z:chebi fb="105" ids="17234">glucose</z:chebi> and energy loss through the urine </plain></SENT>
<SENT sid="2" pm="."><plain>The observation that individuals with familial renal <z:hpo ids='HP_0003076'>glycosuria</z:hpo> maintain <z:mpath ids='MPATH_458'>normal</z:mpath> long-term kidney function provides some reassurance that this mode of action will not adversely affect renal function </plain></SENT>
<SENT sid="3" pm="."><plain>Intense research in this therapeutic area has led to the discovery of novel SGLT2 inhibitors, each with different chemical, pharmacodynamic and pharmacokinetic profiles </plain></SENT>
<SENT sid="4" pm="."><plain>This review outlines the biology, expression and pleotropic activity of the SGLT system and the pharmacological profile of SGLT2 inhibitors and provides a summary of preclinical and limited clinical data available to characterize the efficacy, safety and potential clinical utility of SGLT2 inhibitors in the management of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>